Indications And Dose
Prevention of secondary case of invasive group A streptococcal infection in patients who are allergic to penicillin ▶BY MOUTH Infection ▶Child 6 months–11 years: 12 mg/kg once daily (max. per dose 500 mg) for 5 days ▶Child 12–17 years: 500 mg once daily for 5 days ▶Adult: 500 mg once daily for 5 days Respiratory-tract infections, otitis media, skin and soft- tissue infections ▶BY MOUTH ▶Child 6 months–17 years: 10 mg/kg once daily (max. per dose 500 mg) for 3 days ▶Child 6 months–17 years (body-weight 15–25 kg): 200 mg once daily for 3 days ▶Child 6 months–17 years (body-weight 26–35 kg): 300 mg once daily for 3 days ▶Child 6 months–17 years (body-weight 36–45 kg): 400 mg once daily for 3 days ▶Child 6 months–17 years (body-weight 46 kg and above): 500 mg once daily for 3 days ▶Adult: 500 mg once daily for 3 days, alternatively initially 500 mg once daily for 1 day, then 250 mg once daily for 4 days Uncomplicated genital chlamydial infections | Non- gonococcal urethritis ▶BY MOUTH ▶Child 12–17 years: 1 g for 1 dose ▶Adult: 1 g for 1 dose Uncomplicated gonorrhoea ▶BY MOUTH ▶Adult: 1 g for 1 dose Lyme disease [erythema migrans and/or non-focal symptoms] ▶BY MOUTH ▶Adult: 500 mg daily for 17 days Mild to moderate typhoid due to multiple-antibacterial resistant organisms ▶BY MOUTH ▶Adult: 500 mg once daily for 7 days Community-acquired pneumonia, low to moderate severity ▶BY MOUTH ▶Adult: 500 mg once daily for 3 days, alternatively initially 500 mg once daily for 1 day, then 250 mg once daily for 4 days Community-acquired pneumonia, high severity ▶INITIALLY BY INTRAVENOUS INFUSION ▶Adult: Initially 500 mg once daily for at least 2 days, then (by mouth) 500 mg once daily for a total duration of 7–10 days Antibacterial prophylaxis for insertion of intra-uterine device ▶BY MOUTH ▶Adult: 1 g for 1 dose l UNLICENSED USE ▶In children Not licensed for prevention of group A streptococcal infection; ▶In adults Azithromycin may be used as detailed below, although these situations are considered outside the scope of its licence: . prevention of group A streptococcal infection; . uncomplicated gonorrhoea; . g Lyme disease h; . mild to moderate typhoid due to multiple-antibacterial resistant organisms; . community-acquired pneumonia (high severity) when oral treatment continues for more than 3 days.
Source page 588